Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.27
EBS's Cash-to-Debt is ranked lower than
80% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. EBS: 1.27 )
Ranked among companies with meaningful Cash-to-Debt only.
EBS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.52  Med: 1.79 Max: No Debt
Current: 1.27
Equity-to-Asset 0.64
EBS's Equity-to-Asset is ranked lower than
54% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EBS: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
EBS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.67 Max: 0.81
Current: 0.64
0.33
0.81
Debt-to-Equity 0.40
EBS's Debt-to-Equity is ranked lower than
62% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. EBS: 0.40 )
Ranked among companies with meaningful Debt-to-Equity only.
EBS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1  Med: 0.28 Max: 0.64
Current: 0.4
0.1
0.64
Interest Coverage 13.19
EBS's Interest Coverage is ranked lower than
85% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. EBS: 13.19 )
Ranked among companies with meaningful Interest Coverage only.
EBS' s Interest Coverage Range Over the Past 10 Years
Min: 10.82  Med: 466.1 Max: 5735.71
Current: 13.19
10.82
5735.71
Piotroski F-Score: 5
Altman Z-Score: 4.53
Beneish M-Score: -2.36
WACC vs ROIC
10.05%
12.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 21.45
EBS's Operating Margin % is ranked higher than
86% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. EBS: 21.45 )
Ranked among companies with meaningful Operating Margin % only.
EBS' s Operating Margin % Range Over the Past 10 Years
Min: 10.63  Med: 17.6 Max: 28.92
Current: 21.45
10.63
28.92
Net Margin % 14.41
EBS's Net Margin % is ranked higher than
82% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. EBS: 14.41 )
Ranked among companies with meaningful Net Margin % only.
EBS' s Net Margin % Range Over the Past 10 Years
Min: 8.35  Med: 11.09 Max: 18.07
Current: 14.41
8.35
18.07
ROE % 12.11
EBS's ROE % is ranked higher than
86% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. EBS: 12.11 )
Ranked among companies with meaningful ROE % only.
EBS' s ROE % Range Over the Past 10 Years
Min: 5.5  Med: 9.3 Max: 16.93
Current: 12.11
5.5
16.93
ROA % 7.56
EBS's ROA % is ranked higher than
87% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. EBS: 7.56 )
Ranked among companies with meaningful ROA % only.
EBS' s ROA % Range Over the Past 10 Years
Min: 4.23  Med: 5.8 Max: 12.24
Current: 7.56
4.23
12.24
ROC (Joel Greenblatt) % 23.11
EBS's ROC (Joel Greenblatt) % is ranked higher than
83% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. EBS: 23.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EBS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.5  Med: 24.3 Max: 41.28
Current: 23.11
11.5
41.28
3-Year Revenue Growth Rate 5.20
EBS's 3-Year Revenue Growth Rate is ranked higher than
53% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. EBS: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EBS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 8.8 Max: 31.3
Current: 5.2
-1.1
31.3
3-Year EBITDA Growth Rate 20.50
EBS's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. EBS: 20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EBS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.4 Max: 46.8
Current: 20.5
0
46.8
3-Year EPS without NRI Growth Rate 16.70
EBS's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. EBS: 16.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EBS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.7  Med: 6.65 Max: 61.7
Current: 16.7
-26.7
61.7
GuruFocus has detected 5 Warning Signs with Emergent BioSolutions Inc $EBS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EBS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

EBS Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
Ken Fisher 453,870 sh (-2.97%)
Jim Simons 1,178,111 sh (-7.54%)
Joel Greenblatt 242,516 sh (-47.88%)
» More
Q4 2016

EBS Guru Trades in Q4 2016

Paul Tudor Jones 9,700 sh (New)
Ken Fisher 418,270 sh (-7.84%)
Jim Simons 883,511 sh (-25.01%)
Joel Greenblatt 165,519 sh (-31.75%)
» More
Q1 2017

EBS Guru Trades in Q1 2017

Ken Fisher 413,020 sh (-1.26%)
Jim Simons 702,711 sh (-20.46%)
Joel Greenblatt 120,168 sh (-27.40%)
Paul Tudor Jones 7,000 sh (-27.84%)
» More
Q2 2017

EBS Guru Trades in Q2 2017

Jim Simons 820,411 sh (+16.75%)
Paul Tudor Jones Sold Out
Ken Fisher 397,335 sh (-3.80%)
Joel Greenblatt 64,033 sh (-46.71%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Reduce -3.80%$28.3 - $34.65 $ 37.6222%397,335
Joel Greenblatt 2017-06-30 Reduce -46.71%0.02%$28.3 - $34.65 $ 37.6222%64,033
Ken Fisher 2017-03-31 Reduce -1.26%$28.36 - $34.66 $ 37.6224%413,020
Joel Greenblatt 2017-03-31 Reduce -27.40%0.02%$28.36 - $34.66 $ 37.6224%120,168
Ken Fisher 2016-12-31 Reduce -7.84%$24.6 - $35.88 $ 37.6225%418,270
Joel Greenblatt 2016-12-31 Reduce -31.75%0.03%$24.6 - $35.88 $ 37.6225%165,519
Ken Fisher 2016-09-30 Reduce -2.97%$26.41 - $31.9 $ 37.6232%453,870
Joel Greenblatt 2016-09-30 Reduce -47.88%0.07%$26.41 - $31.9 $ 37.6232%242,516
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AKCA, NAS:XLRN, NAS:INVA, NAS:MYOK, NYSE:CBM, NYSE:BHVN, NAS:LXRX, NAS:ARRY, NAS:DVAX, NAS:IMMU, NAS:RGEN, NAS:GBT, NAS:SGMO, NAS:AIMT, NAS:ESPR, NAS:CORT, NAS:DERM, NAS:ACOR, NAS:FPRX, NAS:INSM » details
Traded in other countries:ER4.Germany,
Headquarter Location:USA
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.

Emergent BioSolutions is a global biotechnology company that offers biopharmaceutical products to healthcare providers and governments. The company has two operating divisions: biodefense and biosciences. Its specialty biodefense division focuses on countermeasures that address public health threats. The U.S. government is the primary purchaser of these products and often provides substantial funding for their development. Emergent's biosciences business is primarily focused on hematology and oncology therapeutics, with a secondary focus on transplantation, infectious disease, and autoimmunity.

Ratios

vs
industry
vs
history
PE Ratio 24.12
EBS's PE Ratio is ranked higher than
55% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. EBS: 24.12 )
Ranked among companies with meaningful PE Ratio only.
EBS' s PE Ratio Range Over the Past 10 Years
Min: 5.26  Med: 21.71 Max: 67.2
Current: 24.12
5.26
67.2
Forward PE Ratio 18.38
EBS's Forward PE Ratio is ranked higher than
52% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. EBS: 18.38 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.11
EBS's PE Ratio without NRI is ranked lower than
51% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. EBS: 26.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
EBS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.26  Med: 20.28 Max: 67.2
Current: 26.11
5.26
67.2
Price-to-Owner-Earnings 36.18
EBS's Price-to-Owner-Earnings is ranked lower than
99.99% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. EBS: 36.18 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EBS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.9  Med: 35.85 Max: 1470
Current: 36.18
5.9
1470
PB Ratio 2.48
EBS's PB Ratio is ranked higher than
71% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. EBS: 2.48 )
Ranked among companies with meaningful PB Ratio only.
EBS' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.83 Max: 3.61
Current: 2.48
0.8
3.61
PS Ratio 3.67
EBS's PS Ratio is ranked higher than
80% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. EBS: 3.67 )
Ranked among companies with meaningful PS Ratio only.
EBS' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.26 Max: 4.1
Current: 3.67
0.77
4.1
Price-to-Free-Cash-Flow 43.77
EBS's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. EBS: 43.77 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EBS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.21  Med: 25 Max: 706.67
Current: 43.77
5.21
706.67
Price-to-Operating-Cash-Flow 17.21
EBS's Price-to-Operating-Cash-Flow is ranked lower than
62% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. EBS: 17.21 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EBS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.79  Med: 13.62 Max: 97.72
Current: 17.21
2.79
97.72
EV-to-EBIT 13.32
EBS's EV-to-EBIT is ranked higher than
64% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. EBS: 13.32 )
Ranked among companies with meaningful EV-to-EBIT only.
EBS' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.9  Med: 11.95 Max: 38.3
Current: 13.32
1.9
38.3
EV-to-EBITDA 9.79
EBS's EV-to-EBITDA is ranked higher than
71% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. EBS: 9.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
EBS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.8  Med: 9.2 Max: 22
Current: 9.79
1.8
22
EV-to-Revenue 2.87
EBS's EV-to-Revenue is ranked higher than
85% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. EBS: 2.87 )
Ranked among companies with meaningful EV-to-Revenue only.
EBS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.6  Med: 2 Max: 4
Current: 2.87
0.6
4
PEG Ratio 0.94
EBS's PEG Ratio is ranked higher than
65% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. EBS: 0.94 )
Ranked among companies with meaningful PEG Ratio only.
EBS' s PEG Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.22 Max: 86.15
Current: 0.94
0.43
86.15
Shiller PE Ratio 35.48
EBS's Shiller PE Ratio is ranked higher than
72% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. EBS: 35.48 )
Ranked among companies with meaningful Shiller PE Ratio only.
EBS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.28  Med: 29.39 Max: 40.87
Current: 35.48
15.28
40.87
Current Ratio 6.99
EBS's Current Ratio is ranked higher than
70% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. EBS: 6.99 )
Ranked among companies with meaningful Current Ratio only.
EBS' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 4.18 Max: 7.22
Current: 6.99
1.22
7.22
Quick Ratio 6.02
EBS's Quick Ratio is ranked higher than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. EBS: 6.02 )
Ranked among companies with meaningful Quick Ratio only.
EBS' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 3.63 Max: 6.18
Current: 6.02
0.76
6.18
Days Inventory 180.75
EBS's Days Inventory is ranked lower than
67% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. EBS: 180.75 )
Ranked among companies with meaningful Days Inventory only.
EBS' s Days Inventory Range Over the Past 10 Years
Min: 87.55  Med: 134.7 Max: 214.89
Current: 180.75
87.55
214.89
Days Sales Outstanding 73.05
EBS's Days Sales Outstanding is ranked lower than
66% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. EBS: 73.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
EBS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.05  Med: 69.18 Max: 124.36
Current: 73.05
36.05
124.36
Days Payable 68.06
EBS's Days Payable is ranked higher than
54% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. EBS: 68.06 )
Ranked among companies with meaningful Days Payable only.
EBS' s Days Payable Range Over the Past 10 Years
Min: 68.06  Med: 162.25 Max: 350.8
Current: 68.06
68.06
350.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.50
EBS's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. EBS: -3.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EBS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.3  Med: -3.8 Max: -1.5
Current: -3.5
-13.3
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 9.67
EBS's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. EBS: 9.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EBS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.39  Med: 6.44 Max: 40.54
Current: 9.67
3.39
40.54
Price-to-Tangible-Book 2.82
EBS's Price-to-Tangible-Book is ranked higher than
73% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. EBS: 2.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EBS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.83  Med: 2.07 Max: 3.7
Current: 2.82
0.83
3.7
Price-to-Intrinsic-Value-Projected-FCF 2.41
EBS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. EBS: 2.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EBS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.06  Med: 1.81 Max: 3.38
Current: 2.41
1.06
3.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.29
EBS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
73% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. EBS: 2.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
EBS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.22  Med: 1.99 Max: 2.26
Current: 2.29
1.22
2.26
Price-to-Median-PS-Value 1.63
EBS's Price-to-Median-PS-Value is ranked lower than
74% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. EBS: 1.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EBS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.97 Max: 1.87
Current: 1.63
0.36
1.87
Price-to-Peter-Lynch-Fair-Value 1.05
EBS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
63% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. EBS: 1.05 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
EBS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.52  Med: 1.06 Max: 7.19
Current: 1.05
0.52
7.19
Price-to-Graham-Number 1.81
EBS's Price-to-Graham-Number is ranked higher than
66% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. EBS: 1.81 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EBS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.48  Med: 1.26 Max: 2.57
Current: 1.81
0.48
2.57
Earnings Yield (Greenblatt) % 7.51
EBS's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. EBS: 7.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EBS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 8.35 Max: 51.8
Current: 7.51
2.6
51.8
Forward Rate of Return (Yacktman) % 28.39
EBS's Forward Rate of Return (Yacktman) % is ranked higher than
74% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. EBS: 28.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EBS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.4  Med: 2.7 Max: 34.5
Current: 28.39
-11.4
34.5

More Statistics

Revenue (TTM) (Mil) $512.21
EPS (TTM) $ 1.56
Beta1.53
Short Percentage of Float8.64%
52-Week Range $24.47 - 38.74
Shares Outstanding (Mil)41.21

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 501 540
EPS ($) 1.58 2.04
EPS without NRI ($) 1.58 2.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure Sep 18 2017 
Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Departm Jul 31 2017 
Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology Jul 26 2017 
Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Cal Jul 20 2017 
Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK Jul 19 2017 
Emergent BioSolutions to Acquire ACAM2000® Business From Sanofi Jul 14 2017 
Biotech Has a Promising Future May 31 2017 
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; W May 11 2017 
Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufac May 10 2017 
Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manuf May 09 2017 

More From Other Websites
Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure Sep 18 2017
See what the IHS Markit Score report has to say about Emergent Biosolutions Inc. Sep 12 2017
Hodges Mutual Fund Aims For Elite Status With Bets On Leading Stocks Like Emergent BioSolutions Sep 11 2017
Emergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue? Sep 04 2017
ETFs with exposure to Emergent BioSolutions, Inc. : August 23, 2017 Aug 23 2017
Edited Transcript of EBS earnings conference call or presentation 3-Aug-17 9:00pm GMT Aug 13 2017
Biotech movers: Ionis Drops After GSK Bows Out of Partnership Aug 11 2017
Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 Aug 10 2017
Emergent Biosolutions Inc Diversifies Its Revenue Aug 07 2017
Emergent Biosolutions misses 2Q profit forecasts Aug 05 2017
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y Aug 04 2017
Erste CEO on Earnings, Czech Housing Market, Brexit Aug 04 2017
Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms... Aug 03 2017
Investor Network: Emergent BioSolutions Inc. to Host Earnings Call Aug 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}